Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus

BACKGROUND: Type 2 diabetes (T2DM) can accelerate the progression of cirrhosis. The potential for oral diabetes medications to counteract the mortality and morbidity of chronic liver diseases is unclear. METHODS: We compared the effectiveness of dual metformin and glucagon-like peptide-1 receptor ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Daniel J., Renelus, Benjamin D., Jamorabo, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433257/
https://www.ncbi.nlm.nih.gov/pubmed/37664227
http://dx.doi.org/10.20524/aog.2023.0814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433257/
https://www.ncbi.nlm.nih.gov/pubmed/37664227
http://dx.doi.org/10.20524/aog.2023.0814

Ejemplares similares